Applied Genetic Technologies Corporation (AGTC) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
14193 NW 119TH TERRACE ALACHUA, FL 32615 |
| State of Incorp. | DE |
| Fiscal Year End | June 30 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 9/30/2022 Q1 | 6/30/2022 Q4 | 3/31/2022 Q3 | 12/31/2021 Q2 | 9/30/2021 Q1 | 6/30/2021 Q4 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments, including: | 34,241 | 67,849 | 72,771 | 90,515 | 107,100 | |||
| Cash and cash equivalents | 34,241 | 67,849 | 72,771 | 90,515 | 105,052 | |||
| Short-term investments | 2,000 | |||||||
| Other undisclosed cash, cash equivalents, and short-term investments | 48 | |||||||
| Other undisclosed current assets | 2,998 | 2,678 | 2,597 | 2,871 | 2,607 | |||
| Total current assets: | 37,239 | 70,527 | 75,368 | 93,386 | 109,707 | |||
| Noncurrent Assets | ||||||||
| Finance lease, right-of-use asset | 11 | 23 | 34 | |||||
| Operating lease, right-of-use asset | 2,890 | 3,029 | 3,167 | 3,059 | 3,167 | |||
| Property, plant and equipment | 4,884 | 4,244 | 4,416 | 4,550 | 4,658 | |||
| Long-term investments and receivables | 7,732 | 7,884 | 7,937 | 7,969 | 8,000 | |||
| Long-term investments | 7,732 | 7,884 | 7,937 | 7,969 | 8,000 | |||
| Intangible assets, net (including goodwill) | 1,541 | 1,381 | 1,345 | 1,303 | 1,287 | |||
| Intangible assets, net (excluding goodwill) | 1,541 | 1,381 | 1,345 | 1,303 | 1,287 | |||
| Restricted cash and investments | 2,921 | |||||||
| Other noncurrent assets | 126 | 126 | 126 | 121 | 113 | |||
| Total noncurrent assets: | 20,094 | 16,664 | 17,002 | 17,025 | 17,259 | |||
| TOTAL ASSETS: | 57,333 | 87,191 | 92,370 | 110,411 | 126,966 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 4,043 | 3,561 | 1,674 | 2,083 | 4,769 | |||
| Accounts payable | 4,043 | 3,561 | 1,674 | 2,083 | 1,879 | |||
| Employee-related liabilities | 2,890 | |||||||
| Debt | 9,532 | 9,070 | 6,727 | 4,444 | 2,219 | |||
| Other undisclosed current liabilities | 13,029 | 13,178 | 15,713 | 15,182 | 12,726 | |||
| Total current liabilities: | 26,604 | 25,809 | 24,114 | 21,709 | 19,714 | |||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 2,530 | 2,900 | 3,133 | 3,218 | 3,418 | |||
| Operating lease, liability | 2,530 | 2,900 | 3,133 | 3,218 | 3,418 | |||
| Liabilities, other than long-term debt | 3,741 | 97 | 95 | 300 | 299 | |||
| Other liabilities | 99 | 97 | 95 | 300 | 299 | |||
| Derivative instruments and hedges, liabilities | 3,642 | |||||||
| Other undisclosed noncurrent liabilities | 6,812 | 11,358 | 13,538 | 15,659 | 17,727 | |||
| Total noncurrent liabilities: | 13,083 | 14,355 | 16,766 | 19,177 | 21,444 | |||
| Total liabilities: | 39,687 | 40,164 | 40,880 | 40,886 | 41,158 | |||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | 17,646 | 47,027 | 51,490 | 69,525 | 85,808 | |||
| Common stock | 68 | 51 | 43 | 43 | 43 | |||
| Treasury stock, value | (256) | (256) | (256) | (256) | (211) | |||
| Additional paid in capital | 344,456 | 337,058 | 327,235 | 326,126 | 325,245 | |||
| Accumulated deficit | (326,622) | (289,826) | (275,532) | (256,388) | (239,269) | |||
| Total stockholders' equity: | 17,646 | 47,027 | 51,490 | 69,525 | 85,808 | |||
| TOTAL LIABILITIES AND EQUITY: | 57,333 | 87,191 | 92,370 | 110,411 | 126,966 | |||
Income Statement (P&L) ($ in thousands) Annual | Quarterly
| 9/30/2022 Q1 | 6/30/2022 Q4 | 3/31/2022 Q3 | 12/31/2021 Q2 | 9/30/2021 Q1 | 6/30/2021 Q4 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 500 | ||||||
| Operating expenses | (17,344) | (13,583) | (18,443) | (16,425) | (14,286) | ||
| Other undisclosed operating income | 500 | ||||||
| Operating loss: | (17,344) | (13,583) | (18,443) | (16,425) | (13,786) | ||
| Nonoperating expense | (991) | (658) | (669) | (663) | (499) | ||
| Investment income, nonoperating | 189 | 9 | 6 | 6 | 10 | ||
| Interest and debt expense | (657) | (667) | (675) | (669) | (509) | ||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 667 | 675 | 669 | 509 | |||
| Loss from continuing operations before equity method investments, income taxes: | (18,992) | (14,241) | (19,112) | (17,088) | (14,285) | ||
| Loss from equity method investments | (75) | (53) | (32) | (31) | (21) | ||
| Loss from continuing operations before income taxes: | (19,067) | (14,294) | (19,144) | (17,119) | (14,306) | ||
| Income tax benefit | 2,170 | ||||||
| Net loss: | (19,067) | (14,294) | (19,144) | (17,119) | (12,136) | ||
| Other undisclosed net income attributable to parent | 657 | ||||||
| Net loss available to common stockholders, diluted: | (18,410) | (14,294) | (19,144) | (17,119) | (12,136) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 9/30/2022 Q1 | 6/30/2022 Q4 | 3/31/2022 Q3 | 12/31/2021 Q2 | 9/30/2021 Q1 | 6/30/2021 Q4 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (19,067) | (14,294) | (19,144) | (17,119) | (12,136) | ||
| Comprehensive loss, net of tax, attributable to parent: | (19,067) | (14,294) | (19,144) | (17,119) | (12,136) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.